Long-term survival of patients treated with BCNU for brain tumors.
The authors present three patients who, after excision and irradiation of their brain tumors, were treated with BCNU for recurrence. All three patients responded well and now are without evidence of tumor, 37, 30, and 36 months after BCNU was stopped. Although these patients represent only a small fraction of those treated with BCNU, they indicate the potential role of chemotherapy in the management of glial tumors.
D000293:Adolescent; D000328:Adult; D001254:Astrocytoma / Q000188:drug therapy / Q000473:pathology; D001853:Bone Marrow / Q000187:drug effects; D001921:Brain / Q000098:blood supply / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004806:Ependymoma / Q000188:drug therapy / Q000473:pathology; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011859:Radiography; D011877:Radionuclide Imaging
D002330:Carmustine